Stand in front of the mineral shelf at any American pharmacy and check the potassium. Almost every bottle says the same thing: 99 mg per tablet. Not 100. Not 250. Ninety-nine.
The National Institutes of Health Office of Dietary Supplements, on its potassium fact sheet for health professionals, notes what that works out to. Ninety-nine milligrams is about 2 percent of the Daily Value for potassium. A multivitamin that contains potassium at all typically provides around 80 mg, and ODS notes that potassium-only products most often contain up to 99 mg. That is why the shelf looks so uniform, and the number is oddly precise.
Most people assume the Food and Drug Administration set that limit. It did not. There is no federal rule capping potassium in a dietary supplement at 99 mg, and the actual explanation runs through a 1975 drug-labeling regulation about damage to the small intestine.
Before any of that, though, the reason the caution exists at all. For a substantial group of Americans, extra potassium is not a wellness question. It is a cardiac one.
Who gets hurt by too much potassium
Hyperkalemia means too much potassium in the blood. Healthy kidneys clear the excess efficiently, which is why the condition is rare in people whose kidneys work normally. The risk concentrates in people whose kidneys cannot keep up, or whose medications stop them from trying.
The NIH Office of Dietary Supplements names the two main groups directly: people with impaired urinary potassium excretion because of chronic kidney disease, and people taking certain medications. For those people, the agency states something that should stop anyone reading a supplement label: even dietary potassium intakes below the Adequate Intake can cause hyperkalemia. Not above. Below.
The federal intake figures carry a matching carve-out. ODS states that the Adequate Intakes do not apply to people with impaired potassium excretion because of a medical condition such as kidney disease, or because of medications that impair excretion. The published number simply is not addressed to them.
ODS lists additional conditions that raise the risk: type 1 diabetes, congestive heart failure, adrenal insufficiency and liver disease.
The medications matter most because they are so common. According to ODS, ACE inhibitors such as benazepril and angiotensin receptor blockers such as losartan reduce urinary potassium excretion, which can lead to hyperkalemia. Potassium-sparing diuretics do the same thing by design: ODS names amiloride and spironolactone, and states that unlike other diuretics these do not increase potassium excretion and can cause hyperkalemia. The agency says experts recommend monitoring potassium status in people taking ACE inhibitors or ARBs.
Two things make this hazard harder to spot than most. First, ODS notes that hyperkalemia can be asymptomatic. Second, when symptoms do appear in severe cases they are not specific: muscle weakness, paralysis, heart palpitations, pins-and-needles sensations, and cardiac arrhythmias that the agency describes as potentially life threatening.
And people with normal kidneys are not categorically exempt. ODS states that very high amounts of potassium supplements, or of salt substitutes containing potassium, could exceed the kidney’s capacity to excrete potassium and cause acute hyperkalemia even in healthy individuals.
Medication and supplement interactions are the subject of article 677, and the list above is where that article starts. ODS is explicit that its own interaction list offers only a few examples, not a complete inventory.
Where the 99 milligrams comes from
The number in the regulation is not 99. It is 100.
Title 21 of the Code of Federal Regulations, section 201.306, is titled “Potassium salt preparations intended for oral ingestion by man.” It sits in Part 201, which governs drug labeling, not in the food or supplement parts of the code. Paragraph (a) deals with coated tablets containing potassium chloride or other potassium salts that supply 100 milligrams or more of potassium per tablet, and says the FDA will not initiate regulatory action against their continued marketing provided specific labeling appears and a new drug application is submitted. Paragraph (b) covers uncoated tablets at the same 100 mg threshold, and liquid preparations supplying 20 milligrams or more of potassium per milliliter, and says the agency may begin regulatory proceedings absent the specified labeling.
The warning the regulation requires concerns reports of nonspecific small-bowel lesions, including narrowing of the intestine with or without ulceration, and in some cases obstruction, hemorrhage and perforation. The regulation directs that the product be stopped if abdominal pain, distension, nausea, vomiting or gastrointestinal bleeding appears.
The dates tell you how old this is. The section was published at 40 FR 13998 on 27 March 1975, and amended at 55 FR 11576 on 29 March 1990 and 67 FR 4906 on 1 February 2002.
Now the part that matters for the supplement aisle. That regulation governs drug products. ODS states that, in accordance with a ruling by Congress, the FDA may not limit the amount of any nutrient, including potassium, in a dietary supplement except for safety-related reasons, and that the agency has not issued a ruling about whether dietary supplements containing more than 99 mg of potassium must carry a warning label. ODS describes the 99 mg figure as a limit that many dietary supplement manufacturers and distributors apply to their own products, out of concern related to potassium-containing drugs.
So the honest description is this: the 99 mg ceiling on potassium supplements is voluntary industry practice, pitched one milligram below the threshold that would pull a product into a drug regulation written in 1975. It is the market reading a drug rule and stopping just short of it, not an FDA limit on supplements.
That distinction has a practical edge. A voluntary convention can change, applies unevenly, and carries no enforcement behind it. It also means the 99 mg on the bottle reflects a 50-year-old finding about intestinal lesions from potassium chloride drug formulations, not a judgment about what is safe for the person holding it.
It is worth sorting this the way the rest of this library sorts any standard on a label. Some requirements are written into regulation. Some are run as government certification programs. Some are verified by an independent third party. And some are simply what the industry does, with no definition behind them. The 99 mg ceiling is in the fourth category, which is the one that looks most like a rule from the outside and is least like one on inspection.
The target numbers were rewritten in 2019
If you have seen 4,700 mg quoted as the amount of potassium adults need, you have seen a figure that stopped being a Dietary Reference Intake seven years ago.
In 2019 a committee of the National Academies of Sciences, Engineering, and Medicine published new Dietary Reference Intakes for sodium and potassium. The current Adequate Intakes, as reported by ODS, are 3,400 mg per day for men aged 19 and over and 2,600 mg per day for women aged 19 and over, with 2,900 mg per day during pregnancy and 2,800 mg per day during lactation. The National Academies’ March 2019 announcement states that the potassium AIs across all age groups range from 2,300 to 3,400 mg per day by sex and life stage, and that these values are lower than the ones established in 2005.
The committee did not set a Recommended Dietary Allowance, because ODS reports it found the data insufficient to derive an Estimated Average Requirement for potassium. An AI is the value set when the evidence cannot support an RDA, and the DRI framework itself is the subject of article 322.
What changed was mostly the method, not the biology. The National Academies Press companion resource for the 2019 report explains that the 2005 AIs were derived from potassium supplement trials, evidence on blood pressure and kidney stone recurrence, and data on bone mineral density. The 2019 AIs were built from something far more mundane: the highest median usual intake observed in national surveys. The report’s potassium chapter, published 5 March 2019, specifies the Canadian Community Health Survey Nutrition 2015 and NHANES 2009 to 2014 as the sources, with adult values drawn from people with normal blood pressure and no self-reported history of cardiovascular disease. The numbers fell for every group except infants.
That is a genuinely important piece of context. The target did not drop because science decided people need less potassium. It dropped because the committee switched from asking what intake produces a health effect to asking what intake people achieve.
The 2019 report also introduced a fifth kind of DRI value, the Chronic Disease Risk Reduction Intake, and found the evidence insufficient to establish one for potassium. That concept belongs to article 322.
Two federal numbers, both current
Meanwhile 4,700 mg has not gone anywhere. Under federal food labeling rules at 21 CFR 101.9, the Daily Value for potassium for adults and children aged 4 and older is 4,700 mg. That is the figure printed on every Nutrition Facts and Supplement Facts panel in the country, and it is the basis for every percent-of-daily-value claim about potassium.
So two federal potassium numbers are simultaneously correct, roughly 1,300 to 2,100 mg apart, depending on which AI you compare. The 3,400 and 2,600 mg figures are the current Adequate Intakes from the 2019 DRI report. The 4,700 mg figure is the current Daily Value under food labeling regulation. They answer different questions, and the one on your label is the older one.
This is also why 99 mg looks so small. Against a 4,700 mg Daily Value, a 99 mg tablet is about 2 percent, as ODS notes. Against the 2,600 mg Adequate Intake for adult women it is still under 4 percent. Either way, a potassium supplement at the conventional dose is not a meaningful share of daily intake, which ODS confirms from a different direction: it reports that supplements do not significantly raise total potassium intake among US adults.
No upper limit does not mean no ceiling
The 2019 committee set no Tolerable Upper Intake Level for potassium. The National Academies state the reason as insufficient evidence to establish one for apparently healthy individuals, and add that this does not mean excessive intake carries no risk. The companion resource makes the same point: potassium still has no UL, as was the case in 2005, and that absence reflects a gap in the evidence rather than a finding of safety.
Three statements have to travel together or the picture misleads. There is no UL for apparently healthy people. Very high supplement or salt-substitute intakes can still cause acute hyperkalemia in healthy people, per ODS. And in people with impaired excretion, intakes below the AI can do it.
Do Americans get enough?
Mostly not, by the published comparison.
ODS reports that among adults aged 20 and over in the 2013 to 2014 National Health and Nutrition Examination Survey, average daily potassium intake from foods was 3,016 mg for men and 2,320 mg for women. Set those beside the 2019 Adequate Intakes of 3,400 mg for men and 2,600 mg for women and both averages fall short. That subtraction is arithmetic, not an agency conclusion. The agency conclusion is ODS’s own: dietary surveys consistently show that people in the United States consume less potassium than recommended, which is why potassium is identified as a nutrient of public health concern.
What that shortfall means for health is less settled than the gap suggests. ODS describes low potassium intake as raising the risk of hypertension, notes that supplement trials have mostly shown blood pressure reductions while a Cochrane review found the reductions not statistically significant, and reports that observational links to stroke are mixed. The agency’s own summary is that more research on both dietary and supplemental potassium is needed before firm conclusions can be drawn. That places most of this in the preliminary bucket rather than the established one.
The foods carrying the most potassium are ordinary ones. ODS points to milk, potatoes and fruit as leading sources in the American diet, which is a useful corrective to the idea that potassium is something bought in a bottle.
One caveat applies to all of the ODS figures above. The agency’s potassium fact sheet for health professionals carries an update date of 2 June 2022. The 2019 reference values and the 1975 drug regulation it describes have not changed since, but the intake data it reports come from a survey cycle that is now more than a decade old.
Salt substitutes are potassium chloride, and that is the real exposure
The product most likely to deliver a large potassium load to an American kitchen is not a supplement. It is the shaker marketed as a salt alternative.
ODS states that many salt substitutes contain potassium chloride replacing some or all of the sodium chloride, and that their potassium content varies widely, from about 440 mg to 2,800 mg of potassium per teaspoon. That is a 6.4-fold range between products sitting on the same shelf. At the top of that range, one teaspoon delivers roughly as much potassium as the entire average daily intake of an American woman.
The evidence on these products is genuinely good and genuinely incomplete, and both halves matter.
A 2022 Cochrane systematic review by Amanda Brand and colleagues pooled 26 randomized trials covering 34,961 adults. Low-sodium salt substitutes probably reduce diastolic blood pressure by 2.43 mmHg and systolic by 4.76 mmHg on average, both moderate-certainty findings. The review also found probable small reductions in non-fatal acute coronary syndrome, about 150 fewer per 100,000 person-years, and in cardiovascular mortality, about 180 fewer per 100,000 person-years. Blood potassium rose slightly, by 0.12 mmol/L.
Then the structural hole. The review states that all 26 trials specifically excluded participants for whom an increased potassium intake is known to be potentially harmful. The benefit estimates come from a population with the vulnerable people removed by design, and the authors say so: there is a lack of evidence in pregnant women and in people for whom higher potassium is potentially harmful, which limits conclusions about safety in the general population.
A 2024 review in Hypertension by Xiaoyue Xu and colleagues looked at how clinical guidelines handle this and found incomplete and inconsistent recommendations across 32 hypertension guidelines and 14 kidney guidelines. The wording the authors proposed to start a consensus debate names the exclusions precisely: everyone with hypertension except people with advanced kidney disease, people using a potassium supplement, people using a potassium-sparing diuretic, or people with another contraindication.
A 2020 modelling study in The BMJ by Matti Marklund and colleagues put numbers on both sides of the ledger for China. Nationwide replacement of discretionary salt with potassium-enriched substitute was estimated to prevent about 461,000 cardiovascular deaths a year while causing an estimated 11,000 additional deaths related to hyperkalemia among people with chronic kidney disease. The modelled net effect was still favorable, including within the kidney disease group. That is a model of one country’s food supply, not a measurement of the United States, and the hyperkalemia deaths are the explicit price of the benefit rather than a hypothetical.
Questions that belong in a clinic, not a checkout line
The decision here is almost never whether potassium is good for people in general. It is whether a particular person’s kidneys and medications can handle a particular load. Four questions get to that faster than any label will.
- Does anything I take reduce how much potassium my kidneys excrete? ACE inhibitors, ARBs and potassium-sparing diuretics are the common ones, and the ODS list is not exhaustive.
- Has my kidney function been measured recently, and what did it show? Chronic kidney disease is the single largest risk factor for hyperkalemia, and early stages produce no symptoms.
- Does the salt substitute in my kitchen contain potassium chloride, and how much per teaspoon? The range across products is more than sixfold.
- Is my potassium level something that should be checked, and how often? A blood potassium result measures what is in the blood at that moment. It does not measure intake, and it does not by itself say what should change.
The one thing worth remembering
The 99 mg on a potassium bottle is not a statement about you. It is the supplement industry stopping one milligram short of a drug regulation that the FDA wrote in 1975 about intestinal lesions, in a part of the code that does not govern supplements at all.
The real potassium risk in American homes sits elsewhere. It is in salt substitutes, which can carry 2,800 mg per teaspoon, and in the combination of ordinary blood pressure medications with kidneys that are not clearing potassium well. For those people, the federal Adequate Intake does not apply, and the published figures were never addressed to them in the first place. That is a clinical question with a blood test attached, and it does not get answered on a shelf.
Keep exploring: vitamin supplement trials and food vs supplements.
Sources
- National Institutes of Health, Office of Dietary Supplements. “Potassium: Fact Sheet for Health Professionals.” ods.od.nih.gov
- U.S. Food and Drug Administration (Electronic Code of Federal Regulations). “21 CFR 201.306, Potassium salt preparations intended for oral ingestion by man.” ecfr.gov
- U.S. Food and Drug Administration (Electronic Code of Federal Regulations). “21 CFR 101.9, Nutrition labeling of food (Reference Daily Intakes).” ecfr.gov
- National Academies of Sciences, Engineering, and Medicine. “Sodium and Potassium Dietary Reference Intake Values Updated in New Report; Introduces New Category for Sodium Based on Chronic Disease Risk Reduction.” nationalacademies.org
- National Academies Press. “Dietary Reference Intakes for Sodium and Potassium: Interactive Resource.” nap.nationalacademies.org
- National Academies of Sciences, Engineering, and Medicine (NCBI Bookshelf). “Potassium: Dietary Reference Intakes for Adequacy, in Dietary Reference Intakes for Sodium and Potassium, 2019.” ncbi.nlm.nih.gov
- PubMed (Cochrane Database of Systematic Reviews). “Brand A, Visser ME, Schoonees A, Naude CE. "Replacing salt with low-sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women." Cochrane Database of Systematic Reviews, 2022. PubMed. DOI: 10.1002/14651858.CD015207.” doi.org
- PubMed (Hypertension). “Xu X, Zeng L, Jha V, et al. "Potassium-Enriched Salt Substitutes: A Review of Recommendations in Clinical Management Guidelines." Hypertension, 2024. PubMed. DOI: 10.1161/HYPERTENSIONAHA.123.21343.” doi.org
- PubMed (The BMJ). “Marklund M, Singh G, Greer R, et al. "Estimated population wide benefits and risks in China of lowering sodium through potassium enriched salt substitution: modelling study." The BMJ, 2020. PubMed. DOI: 10.1136/bmj.m824.” doi.org